Direct Targeting of CREB1 with Imperatorin Inhibits TGFβ2‐ERK Signaling to Suppress Esophageal Cancer Metastasis. Issue 16 (1st July 2020)
- Record Type:
- Journal Article
- Title:
- Direct Targeting of CREB1 with Imperatorin Inhibits TGFβ2‐ERK Signaling to Suppress Esophageal Cancer Metastasis. Issue 16 (1st July 2020)
- Main Title:
- Direct Targeting of CREB1 with Imperatorin Inhibits TGFβ2‐ERK Signaling to Suppress Esophageal Cancer Metastasis
- Authors:
- Xu, Wen Wen
Huang, Zhi‐Hao
Liao, Long
Zhang, Qi‐Hua
Li, Jun‐Qi
Zheng, Can‐Can
He, Yan
Luo, Ting‐Ting
Wang, Yang
Hu, Hui‐Fang
Zuo, Qian
Chen, Wen‐You
Yang, Qing‐Sheng
Zhao, Jian‐Fu
Qin, Yan‐Ru
Xu, Li‐Yan
Li, En‐Min
Liao, Hua‐Xin
Li, Bin
He, Qing‐Yu - Abstract:
- Abstract: Metastasis accounts for 90% of cancer death worldwide, and effective therapeutic strategies are lacking. The aim of this work is to identify the key drivers in tumor metastasis and screen therapeutics for treatment of esophageal squamous cell carcinoma (ESCC). Gene Ontology analysis of The Cancer Genome Atlas (TCGA) gene expression datasets of ESCC patients with or without lympy metastasis identifies that TGF β 2 is highly enriched in the pathways essential for tumor metastasis and upregulates in the metastatic ESCC tumors. High TGF β 2 expression in ESCC correlates with metastasis and patient survival, and functionally contributes to tumor metastasis via activating extracellular signal‐regulated kinases (ERK) signaling. By screening of a library consisting of 429 bioactive compounds, imperatorin is verified as a novel TGF β 2 inhibitor, with robustly suppressive effect on tumor metastasis in multiple mice models. Mechanistically, direct binding of imperatorin and CREB1 inhibits phosphorylation, nuclear translocation of CREB1, and its interaction with TGF β 2 promoter, represses TGF β 2 expression and fibroblasts‐secreted CCL2, and then inactivates ERK signaling to block cancer invasion and abrogates the paracrine effects of fibroblasts on tumor angiogenesis and metastasis. Overall, the findings suggest the use of TGF β 2 as a diagnostic and prognostic biomarker and therapeutic target in ESCC, and supports the potential of imperatorin as a novel therapeuticAbstract: Metastasis accounts for 90% of cancer death worldwide, and effective therapeutic strategies are lacking. The aim of this work is to identify the key drivers in tumor metastasis and screen therapeutics for treatment of esophageal squamous cell carcinoma (ESCC). Gene Ontology analysis of The Cancer Genome Atlas (TCGA) gene expression datasets of ESCC patients with or without lympy metastasis identifies that TGF β 2 is highly enriched in the pathways essential for tumor metastasis and upregulates in the metastatic ESCC tumors. High TGF β 2 expression in ESCC correlates with metastasis and patient survival, and functionally contributes to tumor metastasis via activating extracellular signal‐regulated kinases (ERK) signaling. By screening of a library consisting of 429 bioactive compounds, imperatorin is verified as a novel TGF β 2 inhibitor, with robustly suppressive effect on tumor metastasis in multiple mice models. Mechanistically, direct binding of imperatorin and CREB1 inhibits phosphorylation, nuclear translocation of CREB1, and its interaction with TGF β 2 promoter, represses TGF β 2 expression and fibroblasts‐secreted CCL2, and then inactivates ERK signaling to block cancer invasion and abrogates the paracrine effects of fibroblasts on tumor angiogenesis and metastasis. Overall, the findings suggest the use of TGF β 2 as a diagnostic and prognostic biomarker and therapeutic target in ESCC, and supports the potential of imperatorin as a novel therapeutic strategy for cancer metastasis. Abstract : This work suggests the clinical and functional role of TGF β 2 in esophageal cancer metastasis. Imperatorin is verified with a robustly suppressive effect on tumor invasion and metastasis in vitro and in vivo. Mechanistically, imperatorin can directly bind with CREB1 and inhibits its phosphorylation and interaction with TGF β 2 promoter, then inactivates extracellular signal‐regulated kinases (ERK) signaling and fibroblasts‐secreted CCL2 to block tumor angiogenesis and metastasis. … (more)
- Is Part Of:
- Advanced science. Volume 7:Issue 16(2020)
- Journal:
- Advanced science
- Issue:
- Volume 7:Issue 16(2020)
- Issue Display:
- Volume 7, Issue 16 (2020)
- Year:
- 2020
- Volume:
- 7
- Issue:
- 16
- Issue Sort Value:
- 2020-0007-0016-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-07-01
- Subjects:
- diagnosis -- esophageal cancer metastasis -- Imperatorin -- prognosis -- TGFβ2 -- therapeutic implications
Science -- Periodicals
505 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2198-3844 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/advs.202000925 ↗
- Languages:
- English
- ISSNs:
- 2198-3844
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13893.xml